The SOCS-1 -1478CA/del Polymorphism is not Associated with Colorectal Cancer or Age at Onset in Turkish Subjects

  • Hartavi, Mustafa (Department of Internal Medicine, Uludag University, Faculty of Medicine) ;
  • Kurt, Ender (Department of Medical Oncology, Uludag University, Faculty of Medicine) ;
  • Oral, Barbaros (Department of Immunology, Uludag University, Faculty of Medicine) ;
  • Olmez, Omer Fatih (Department of Medical Oncology, Uludag University, Faculty of Medicine) ;
  • Cubukcu, Erdem (Department of Medical Oncology, Uludag University, Faculty of Medicine) ;
  • Deligonul, Adem (Department of Medical Oncology, Uludag University, Faculty of Medicine) ;
  • Avci, Nilufer (Department of Medical Oncology, Uludag University, Faculty of Medicine) ;
  • Manavoglu, Osman (Department of Medical Oncology, Uludag University, Faculty of Medicine)
  • Published : 2013.12.31


Background: Suppressor of cytokine signaling (SOCS)-1 acts as a key regulator of many cytokine signaling pathways and its abnormal expression has been identified in several human malignancies, suggesting potential roles in carcinogenesis. The aim of this study was to investigate any association between the functional SOCS-1 -1478CA>del polymorphism and colorectal cancer (CC) as well as age at onset in a Turkish clinical sample. Materials and Methods: A total of 122 subjects were enrolled in this case-control study (70 CC cases and 52 controls). The SOCS-1 -1478CA>del polymorphism was genotyped using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results: The odds ratio of the del allele for CC relative to the CA allele was not significantly different between the groups (OR=0.71, 95% CI=0.41-1.22, p=0.27). This result did not change after adjustment for age and sex on multivariable regression analysis (OR=0.84, 95% CI=0.59-1.34, p=0.53). When the SOCS-1 -1478CA>del polymorphism was analyzed among CC patients in relation to the age at disease onset, we found no significant differences between subjects with the del/del, CA/del, and CA/CA genotypes. Conclusions: The results of our study did not point towards a major role of the SOCS-1 -1478CA>del polymorphism in the pathogenesis of CC in Turkish subjects.


  1. Aiello M, Vella N, Cannavo C, et al (2011). Role of genetic polymorphisms and mutations in colorectal cancer therapy. Mol Med Rep, 4, 203-8.
  2. Armaghany T, Wilson JD, Chu Q, Mills G (2012). Genetic alterations in colorectal cancer. Gastrointest Cancer Res, 5, 19-27.
  3. Arthur JC, Jobin C (2011). The struggle within: microbial influences on colorectal cancer. Inflamm Bowel Dis, 17, 396-409.
  4. Boland CR (2010). Chronic inflammation, colorectal cancer and gene polymorphisms. Dig Dis, 28, 590-5.
  5. Brenner H, Hoffmeister M, Stegmaier C, et al (2007). Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies. Gut, 56, 1585-9.
  6. Carvalho B, Sillars-Hardebol AH, Postma C, et al (2012). Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism. Cell Oncol (Dordr), 35, 53-63.
  7. Castellvi-Bel S, Ruiz-Ponte C, Fernandez-Rozadilla C, et al (2012). Seeking genetic susceptibility variants for colorectal cancer: the EPICOLON consortium experience. Mutagenesis, 27, 153-9.
  8. Chan HC, Ke LY, Liu CC, et al (2010). Increased expression of suppressor of cytokine signaling 1 mRNA in patients with rheumatoid arthritis. Kaohsiung J Med Sci, 26, 290-8.
  9. Chinen T, Kobayashi T, Ogata H, et al (2006). Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFNgamma and IL-4 are involved. Gastroenterol, 130, 373-88.
  10. Coghill AE, Newcomb PA, Poole EM, et al (2011). Genetic variation in inflammatory pathways is related to colorectal cancer survival. Clin Cancer Res, 17, 7139-47.
  11. Cunningham D, Atkin W, Lenz HJ, et al (2010). Colorectal cancer. Lancet, 375, 1030-47.
  12. Eaden JA, Abrams KR, Mayberry JF (2001). The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 48, 526-35.
  13. Emanuele E, Fontana JM, Minoretti P, Geroldi D (2010) Preliminary evidence of a genetic association between chromosome 9p21.3 and human longevity. Rejuvenation Res, 13, 23-6.
  14. Fearon ER (2011). Molecular genetics of colorectal cancer. Ann Rev Pathol, 6, 479-507.
  15. Fernandez E, Gallus S, La Vecchia C, et al (2004). Family history and environmental risk factors for colon cancer. Cancer Epidemiol Biomarkers Prev, 13, 658-61.
  16. Freeman HJ (2008). Colorectal cancer risk in Crohn's disease. World J Gastroenterol, 14, 1810-1.
  17. Goel A, Boland CR (2010). Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol, 26, 47-52.
  18. Gylvin T, Ek J, Nolsoe R, et al (2009). Functional SOCS1 polymorphisms are associated with variation in obesity in whites. Diabetes Obes Metab, 11, 196-203.
  19. Haggar FA, Boushey RP (2009). Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg, 22, 191-7.
  20. Hanada T, Kobayashi T, Chinen T, et al (2006). IFN gammadependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med, 203, 1391-7.
  21. Harada M, Nakashima K, Hirota T, et al (2007) Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. Am J Respir Cell Mol Biol, 36, 491-6.
  22. Landi S, Bottari F, Gemignani F, et al (2007). Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. Eur J Cancer, 43, 762-8.
  23. Lin OS (2009). Acquired risk factors for colorectal cancer. Methods Mol Biol, 472, 361-72.
  24. Lin SY, Yeh KT, Chen WT, et al (2004). Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features. Oncol Rep, 11, 341-8.
  25. Losman JA, Chen XP, Hilton D, Rothman P (1999). Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. J Immunol, 162, 3770-4.
  26. Ohya Ki, Kajigaya S, Yamashita Y, et al (1997). SOCS-1/JAB/ SSI-1 can bind to and suppress Tec protein-tyrosine kinase. J Biol Chem, 272, 27178-82.
  27. Piganis RA, De Weerd NA, Gould JA, et al (2011). Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem, 286, 33811-8.
  28. Slattery ML, Lundgreen A, Bondurant KL, Wolff RK (2011). Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis, 32, 1660-7.
  29. Sugai T, Takahashi H, Habano W, et al (2003). Analysis of genetic alterations, classified according to their DNA ploidy pattern, in the progression of colorectal adenomas and early colorectal carcinomas. J Pathol, 200, 168-76.
  30. Terzic J, Grivennikov S, Karin E, Karin M (2010). Inflammation and colon cancer. Gastroenterol, 138, 2101-21.
  31. Ullman TA, Itzkowitz SH (2011). Intestinal inflammation and cancer. Gastroenterol, 140, 1807-16.
  32. Zhang J, Li H, Yu JP, Wang SE, Ren XB (2012). Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer, 130, 1971-80.
  33. Fujitake S, Hibi K, Okochi O, et al (2004). Aberrant methylation of SOCS-1 was observed in younger colorectal cancer patients. J Gastroenterol, 39, 120-4.